Reports
Sale
Global Contract Development and Manufacturing Organization (CDMO) Market: By Service Type CMO: Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Development and Manufacturing; By Research Phase CRO; By Therapeutic Area; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032
Global Contract Development and Manufacturing Organization (CDMO) Market Outlook
The global contract development and manufacturing organization (CDMO) market size was valued at USD 225.58 billion in 2023, driven by rising demand for novel drugs and therapies to treat chronic diseases across the globe. The market is expected to grow at a CAGR of 9.1% during the forecast period of 2024-2032, with the values likely to rise from USD 244.53 billion in 2024 to USD 489.99 billion by 2032.
-Market.png)
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Contract Development and Manufacturing Organization (CDMO) Market Overview
Contract development and manufacturing organization (CDMO) refers to an organization that partners with pharmaceutical companies to provide drug development and manufacturing services on a contractual basis. CDMO can help these firms outsource the manufacturing of drugs as well as assist in the development activities involved before the manufacturing process. Partnering with a CDMO offers multiple benefits to the pharmaceutical company such as reduced infrastructure costs, expertise from skilled staff, and necessary manufacturing capacity to increase production.
According to the data released by the World Health Organisation (WHO), chronic diseases or non-communicable diseases cause 41 million deaths every year, accounting for 74% of deaths globally. The prevalence of these chronic diseases, including cardiovascular diseases, cancer, and diabetes, responsible for increasing mortality rates, fuels the need for effective treatment options like novel drugs and therapies. Subsequently, this elevates the contract development and manufacturing organization (CDMO) market demand as more and more pharmaceutical companies are opting for such services to offer improved and efficient solutions to patients.
Increased Mergers and Acquisitions to Expedite Drug Development and Delivery
Contract development and manufacturing organizations (CDMOs) are increasingly engaging in mergers and acquisitions to keep up with changing customer requirements, which is a significant trend aiding market growth. In June 2023, KBI Biopharma, Inc., a cell line development CDMO, merged with Selexis SA, a global life sciences company, integrating as one organization under the name KBI Biopharma. This merger event will streamline drug development and manufacturing processes, including clinical and cGMP manufacturing services for mammalian programs.
Strategic partnerships can reduce manufacturing risks and accelerate the commercialization process of drugs by employing integrated resources and solutions. In January 2024, Kindeva Drug Delivery (a global CDMO specializing in drug-device combination products), announced the acquisition of Summit Biosciences Inc. (an intranasal drug delivery CDMO in the United States), to enhance its drug delivery capabilities and expand its biopharma customer base. The acquisition aims to offer improved intranasal drug delivery options in the coming years.
Strategic Investments Reinforce Contract Development and Manufacturing Organization (CDMO) Market Growth and Expansion
In July 2023, a leading biopharmaceuticals CDMO, Biovian announced its decision to invest EUR 50 million to facilitate the expansion of its manufacturing unit in Finland. The facility will be constructed in an area of 69,000 sq. ft, harboring advanced technologies to aid the development of Advanced Therapy Medical Products (ATMP), including adeno-associated viral therapies. The investment will help in increasing the production capacity of the company to align with the growing size of the CDMO market.
To meet the rising market demand, CDMOs are rapidly expanding their manufacturing capacities and capabilities to deliver optimal services to their customers at a larger scale. Strategic investments have enabled the leading CDMO players in the market to adapt to the changing landscape in the biopharmaceutical industry.
-Market-by-service.png)
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Contract Development and Manufacturing Organization (CDMO) Market Segmentation
Market Breakup by Service Type CMO
- Active Pharmaceutical Ingredient (API) Manufacturing
- Small Molecule
- Large Molecule
- High Potency (HPAPI)
- Finished Dosage Formulation (FDF) Development and Manufacturing
- Solid Dose Formulation
- Liquid Dose Formulation
- Injectable Dose Formulation
- Secondary Packaging Services
Market Breakup by Research Phase CRO
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Phase IV
Market Breakup by Therapeutic Area
- Oncological Diseases
- Cardiovascular Diseases
- Infectious Diseases
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
-Market-by-region.png)
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Contract Development and Manufacturing Organization (CDMO) Market Regional Analysis
North America has been leading the contract development and manufacturing organization (CDMO) market during the historical period. This can be attributed to the presence of top CDMO players in the region who are constantly making investments and taking mergers and acquisitions initiatives to upscale their drug manufacturing capacities. In January 2023, a United States-based CDMO, Agilent Technologies reported a USD 725 million investment to double its manufacturing capacity. The investment was made to accommodate the surge in the therapeutic nucleic acids market and develop drugs targeting prevalent diseases like cancer and cardiovascular diseases.
Europe is another major market expected to hold a substantial contract development and manufacturing organization (CDMO) market share in the coming years. The robust medical infrastructure and advanced healthcare system drive the demand for novel drugs and vaccines to treat and prevent chronic diseases. Consequently, the major biopharmaceutical firms are working towards catering to the unmet medical needs of the patients.
Global Contract Development and Manufacturing Organization (CDMO) Market: Competitor Landscape
In January 2023, Lottee Biologics, a CDMO company headquartered in South Korea, announced its investment plan of USD 3 billion to build three mega plants, each with a production capacity of 360,000 liters by 2030. The company is expected to begin commercial production by 2027, aiming to generate USD 3 billion in revenue by 2034 and bolster the biopharma ecosystem, thereby accelerating the discovery of new therapeutics. The rising trend of internal investments by prominent biopharmaceutical companies is anticipated to increase the contract development and manufacturing organization (CDMO) market size in the forecast period.
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Catalant Inc.
- Baxter Biopharma Solutions (Baxter International Inc.)
- Vetter Pharma-Fertigung GmbH & Co. KG
- Recipharm AB
- Albany Moleculer Research Inc. (AMRI)
- Thermo Fisher Scientific
- Boehringer Ingelheim Group
- Pfizer Inc.
- NextPharma Technologies
- Jubilant Pharmova Ltd
- Famar SA
- Lonza Group
- TapeMark
- Novotech Pty Ltd
- ARX LLC
- Aenova Holding GmBH
- Tesa Labtec GmbH (TESA SE)
- CMIC Holdings Company Ltd
- Syneos Health Inc.
- LabCorp Drug Development
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Service Type |
|
| Breakup by Research Phase |
|
|
Breakup by Therapeutic Area |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Contract Development and Manufacturing Organisation (CDMO) Market Overview
3.1 Global Contract Development and Manufacturing Organisation (CDMO) Market Historical Value (2017-2023)
3.2 Global Contract Development and Manufacturing Organisation (CDMO) Market Forecast Value (2024-203)
4 Global Contract Development and Manufacturing Organisation (CDMO) Market Landscape*
4.1 Contract Development and Manufacturing Organisation (CDMO): Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Contract Development and Manufacturing Organisation (CDMO): Service Landscape
4.2.1 Analysis by Service Type CMO
4.2.2 Analysis by Therapeutic Area
4.2.3 Analysis by Research Phase CRO
5 Global Contract Development and Manufacturing Organisation (CDMO) Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Contract Development and Manufacturing Organisation (CDMO) Market Segmentation (2017-2032)
6.1 Global Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Service Type CMO
6.1.1 Market Overview
6.1.2 Active Pharmaceutical Ingredient (API) Manufacturing
6.1.2.1 Small Molecule
6.1.2.2 Large Molecule
6.1.2.3 High Potency (HPAPI)
6.1.3 Finished Dosage Formulation (FDF) Development and Manufacturing
6.1.3.1 Solid Dose Formulation
6.1.3.2 Liquid Dose Formulation
6.1.3.3 Injectable Dose Formulation
6.1.4 Secondary Packaging Services
6.2 Global Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Research Phase CRO
6.2.1 Pre-clinical
6.2.2 Phase I
6.2.3 Phase II
6.2.4 Phase III
6.2.5 Phase IV
6.3 Global Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Therapeutic Area
6.3.1 Market Overview
6.3.2 Oncological Diseases
6.3.3 Cardiovascular Diseases
6.3.4 Infectious Diseases
6.3.5 Others
6.4 Global Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Region
6.4.1 North America
6.4.2 Europe
6.4.3 Asia Pacific
6.4.4 Latin America
6.4.5 Middle East and Africa
7 North America Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032)
7.1 North America Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Service Type CMO
7.1.1 Market Overview
7.1.2 Active Pharmaceutical Ingredient (API) Manufacturing
7.1.2.1 Small Molecule
7.1.2.2 Large Molecule
7.1.2.3 High Potency (HPAPI)
7.1.3 Finished Dosage Formulation (FDF) Development and Manufacturing
7.1.3.1 Solid Dose Formulation
7.1.3.2 Liquid Dose Formulation
7.1.3.3 Injectable Dose Formulation
7.1.4 Secondary Packaging Services
7.2 North America Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Research Phase CRO
7.2.1 Pre-clinical
7.2.2 Phase I
7.2.3 Phase II
7.2.4 Phase III
7.2.5 Phase IV
7.3 North America Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032)
8.1 Europe Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Service Type CMO
8.1.1 Market Overview
8.1.2 Active Pharmaceutical Ingredient (API) Manufacturing
8.1.2.1 Small Molecule
8.1.2.2 Large Molecule
8.1.2.3 High Potency (HPAPI)
8.1.3 Finished Dosage Formulation (FDF) Development and Manufacturing
8.1.3.1 Solid Dose Formulation (Tablets)
8.1.3.2 Liquid Dose Formulation
8.1.3.3 Injectable Dose Formulation
8.1.4 Secondary Packaging Services
8.2 Europe Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Research Phase CRO
8.2.1 Pre-clinical
8.2.2 Phase I
8.2.3 Phase II
8.2.4 Phase III
8.2.5 Phase IV
8.3 Europe Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032)
9.1 Asia Pacific Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Service Type CMO
9.1.1 Market Overview
9.1.2 Active Pharmaceutical Ingredient (API) Manufacturing
9.1.2.1 Small Molecule
9.1.2.2 Large Molecule
9.1.2.3 High Potency (HPAPI)
9.1.3 Finished Dosage Formulation (FDF) Development and Manufacturing
9.1.3.1 Solid Dose Formulation (Tablets)
9.1.3.2 Liquid Dose Formulation
9.1.3.3 Injectable Dose Formulation
9.1.4 Secondary Packaging Services
9.2 Asia Pacific Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Research Phase CRO
9.2.1 Pre-clinical
9.2.2 Phase I
9.2.3 Phase II
9.2.4 Phase III
9.2.5 Phase IV
9.3 Asia Pacific Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 Australia
9.3.5 ASEAN
9.3.6 Others
10 Latin America Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032)
10.1 Latin America Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Service Type CMO
10.1.1 Market Overview
10.1.2 Active Pharmaceutical Ingredient (API) Manufacturing
10.1.2.1 Small Molecule
10.1.2.2 Large Molecule
10.1.2.3 High Potency (HPAPI)
10.1.3 Finished Dosage Formulation (FDF) Development and Manufacturing
10.1.3.1 Solid Dose Formulation (Tablets)
10.1.3.2 Liquid Dose Formulation
10.1.3.3 Injectable Dose Formulation
10.1.4 Secondary Packaging Services
10.2 Latin America Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Research Phase CRO
10.2.1 Pre-clinical
10.2.2 Phase I
10.2.3 Phase II
10.2.4 Phase III
10.2.5 Phase IV
10.3 Latin America Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032)
11.1 Middle East and Africa Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Service Type CMO
11.1.1 Market Overview
11.1.2 Active Pharmaceutical Ingredient (API) Manufacturing
11.1.2.1 Small Molecule
11.1.2.2 Large Molecule
11.1.2.3 High Potency (HPAPI)
11.1.3 Finished Dosage Formulation (FDF) Development and Manufacturing
11.1.3.1 Solid Dose Formulation (Tablets)
11.1.3.2 Liquid Dose Formulation
11.1.3.3 Injectable Dose Formulation
11.1.4 Secondary Packaging Services
11.2 Middle East and Africa Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Research Phase CRO
11.2.1 Pre-clinical
11.2.2 Phase I
11.2.3 Phase II
11.2.4 Phase III
11.2.5 Phase IV
11.3 Middle East and Africa Contract Development and Manufacturing Organisation (CDMO) Market (2017-2032) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Catalant Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Baxter Biopharma Solutions (Baxter International Inc.)
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Vetter Pharma-Fertigung GmbH & Co. KG
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Recipharm AB
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Albany Moleculer Research Inc. (AMRI)
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Thermo Fisher Scientific
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Boehringer Ingelheim Group
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Pfizer Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 NextPharma Technologies
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Jubilant Pharmova Ltd
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Famar SA
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Lonza Group
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 TapeMark
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Novotech Pty Ltd
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 ARX LLC
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
17.16 Aenova Holding GmBH
17.16.1 Financial Analysis
17.16.2 Product Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisitions
17.16.5 Certifications
17.17 Tesa Labtec GmbH (TESA SE)
17.17.1 Financial Analysis
17.17.2 Product Portfolio
17.17.3 Demographic Reach and Achievements
17.17.4 Mergers and Acquisitions
17.17.5 Certifications
17.18 CMIC Holdings Company Ltd
17.18.1 Financial Analysis
17.18.2 Product Portfolio
17.18.3 Demographic Reach and Achievements
17.18.4 Mergers and Acquisitions
17.18.5 Certifications
17.19 Syneos Health Inc.
17.19.1 Financial Analysis
17.19.2 Product Portfolio
17.19.3 Demographic Reach and Achievements
17.19.4 Mergers and Acquisitions
17.19.5 Certifications
17.20 LabCorp Drug Development
17.20.1 Financial Analysis
17.20.2 Product Portfolio
17.20.3 Demographic Reach and Achievements
17.20.4 Mergers and Acquisitions
17.20.5 Certifications
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
What was the global contract development and manufacturing organization (CDMO) market value in 2023?
The market attained a value of about USD 225.58 billion in 2023, driven by the rising demand for novel drugs and therapies to treat chronic diseases across the globe.
The market is anticipated to grow at a CAGR of 9.1% during the forecast period of 2024-2032, likely to reach a market value of USD 489.99 billion by 2032.
The market demand is driven by the increase in the healthcare investments, disposable incomes, and the need for effective drugs to supplement the growth of the healthcare sector.
The increased mergers and acquisitions by prominent companies are one of the key market trends aiding the CDMO market growth. In January 2024, Kindeva Drug Delivery acquired Summit Biosciences Inc. to enhance its intranasal drug delivery capabilities.
The various services available in the market include active pharmaceutical ingredient (API) manufacturing, finished dosage formulation (FDF) development and manufacturing, and secondary packaging services. Active pharmaceutical ingredient (API) manufacturing is further segmented into small molecule, large molecule, and high potency (HPAPI), whereas finished dosage formulation (FDF) development and manufacturing includes solid, liquid, and injectable dose formulation.
What is the market breakup market based on the research phase CRO (Contract Research Organisations)?
Based on the research phase CRO, the market is segmented into pre-clinical, phase I, phase II, phase III, and phase IV.
Based on the therapeutic area, the market is segmented into oncological, cardiovascular, and infectious diseases, among others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa.
Key players involved in the market are Catalant Inc., Baxter Biopharma Solutions (Baxter International Inc.), Vetter Pharma-Fertigung GmbH & Co. KG, Recipharm AB, Albany Moleculer Research Inc. (AMRI), Thermo Fisher Scientific, Boehringer Ingelheim Group, Pfizer Inc., NextPharma Technologies, Jubilant Pharmova Ltd, Famar SA, Lonza Group, TapeMark, Novotech Pty Ltd, ARX LLC, Aenova Holding GmBH, Tesa Labtec GmbH (TESA SE), CMIC Holdings Company Ltd, Syneos Health Inc., and LabCorp Drug Development.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER